In last trading session, Coherus Biosciences Inc (NASDAQ:CHRS) saw 1.5 million shares changing hands with its beta currently measuring 0.92. Company’s recent per share price level of $1.10 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $127.48M. That closing price of CHRS’s stock is at a discount of -152.73% from its 52-week high price of $2.78 and is indicating a premium of 40.0% from its 52-week low price of $0.66.
For Coherus Biosciences Inc (CHRS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.13 in the current quarter.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Coherus Biosciences Inc’s shares saw a change of -20.29% in year-to-date performance and have moved -1.79% in past 5-day. Coherus Biosciences Inc (NASDAQ:CHRS) showed a performance of -16.67% in past 30-days.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 81.67% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -445.45% in reaching the projected high whereas dropping to the targeted low would mean a loss of -445.45% for stock’s current value.
Coherus Biosciences Inc (CHRS) estimates and forecasts
This year revenue growth is estimated to fall -0.65% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 43.88M for the same. And 1 analysts are in estimates of company making revenue of 60M in the next quarter. Company posted 91.52M and 77.06M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.73% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 113.96% while estimates for its earnings growth in next 5 years are of 33.84%.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
BLACKROCK INC. is the top institutional holder at CHRS for having 11.75 million shares of worth $20.33 million. And as of 2024-06-30, it was holding 10.4236 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.6 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.4035 of outstanding shares, having a total worth of $18.34 million.
